Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/44356
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Extended dosing intervals with erythropoiesis-stimulating agents in chronic kidney disease: a review of clinical data |
Author: | Carrera, F. Disney, A. Molina, M. |
Citation: | Nephrology Dialysis Transplantation, 2007; 22(4):19-30 |
Publisher: | Oxford Univ Press |
Issue Date: | 2007 |
ISSN: | 0931-0509 1460-2385 |
Statement of Responsibility: | Fernando Carrera, Alex Disney and Manuel Molina |
Abstract: | The recombinant human erythropoietins epoetins alfa and beta have relatively short half-lives (24 h by subcutaneous route) and have traditionally been administered 2 or 3 times a week for the treatment of anaemia in patients with chronic kidney disease. However, multiple weekly injections are inconvenient for both the patient and the healthcare provider. With the introduction of the longer-acting erythropoiesis-stimulating agent darbepoetin alfa, there has been growing interest in longer dosing intervals for erythropoiesis-stimulating agents. Data from several randomized studies have shown that darbepoetin alfa is effective in maintaining haemoglobin levels when administered (subcutaneously, intravenously or both) every 2 weeks in dialysis patients, and every 2 weeks or monthly in patients with chronic kidney disease not yet receiving dialysis. Moreover, intravenous administration with darbepoetin alfa does not require a higher dosage compared with the subcutaneous route. Epoetins alfa and beta have also been studied in similar schedules, although few data from well-designed studies are available. Current data suggest that once-weekly administration of these forms of epoetin is feasible in dialysis patients, but dose increases are often required when switching patients from traditional twice- or thrice-weekly schedules. Also, administration of epoetins every other week is feasible in selected patients with chronic renal insufficiency. Further study is required to clarify the optimum schedule for epoetins in these settings. |
Keywords: | anaemia chronic kidney disease darbepoetin alfa dosing schedule erythropoiesis-stimulating agents extended dosing intervals |
Description: | © The Author [2007]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. for Permissions, please email: journals.permissions@oxfordjournals.org |
DOI: | 10.1093/ndt/gfm162 |
Published version: | http://ndt.oxfordjournals.org/cgi/content/abstract/22/suppl_4/iv19 |
Appears in Collections: | Aurora harvest 6 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.